-The Indian Express The 612 Indians on the list of those who have invested in tax havens such as the British Virgin Islands include two MPs, a former royal and top industrialists. RITU SARIN puts together details of 20 among them SONU LALCHAND MIRCHANDANI Mirchandani is the founder of popular consumer electronics firm Onida. Mirchandani and his wife, Soni, opened a BVI company called Strong Wing Overseas Ltd in 2006 with an authorised...

-The Indian Express Report finds govt did not recover dues of Rs 750 cr from distributors. At a time when the opposition BJP plans to intensify protests against power tariff in Delhi, the Comptroller and Auditor General (CAG) of India's report for the 2011-12 fiscal has slammed the Delhi government for not recovering dues to the tune of Rs 750 crore from private distribution Companies. The report, tabled on Tuesday in the Delhi...

-The Business Standard Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG's patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker. This is because the judgement...

-The Business Standard Interview with Founder chairman of Cancer Patients Aid Association Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting. Sapru, founder chairman of Cancer Patients Aid Association, or CPAA (which moved the Supreme Court to keep the prices of the cancer drug low), tells Sushmi Dey what the judgment means to cancer patients....

-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...